RAM has received research contracts during the last 5 years from Bio-Rad Laboratories, Focus Diagnostics and GlaxoSmithKline, and speaker honoraria or consulting fees from Biokit USA and Roche Diagnostics. DW was supported by an unrestricted educational training grant from the University of North Carolina (NC-GSK) Center for Excellence in Pharmacoepidemiology and Public Health, University of North Carolina School of Public Health and NIH/NIAID 5 T32 AI 07001-31 Training in Sexually Transmitted Diseases and AIDS.Д¬ompeting interests: WH is a full-time employee of Focus Diagnostics. SM was the recipient of an Investigator Award from the CIHR. Before HSV-2 seropositivity may be reliably reported in selected areas of Africa, performance studies of HSV-2 serological assays in individual geographical areas are recommended.ДЇunding: This study was supported by a RO1 grant from the National Cancer Institute, National Institutes of Health (NIH) (CA114773-01) by grant number AI50440 from the Division of AIDS, National Institute of Allergies and Infectious Disease, NIH and by grant number HCT 44180 from the Canadian Institutes of Health Research (CIHR). Further understanding is needed for the interpretation of HSV-2 inhibition or ELISA test positive/ Western blot seronegative results. Overall, the Kalon ELISA performed better than the HerpeSelect ELISA in these young men from Kisumu. Using the inhibition test as the reference standard, the sensitivity of the Western blot appeared low (49%).Д¬onclusions: In men in western Kenya who were HIV seronegative, the HerpeSelect and Kalon type-specific ELISAs had high sensitivities yet limited specificities using the Western blot as reference standard. The sensitivity and specificity of the Kalon test versus the Western blot were 92% and 79%, respectively, and 80% and 82% versus the inhibition test. Similar results were obtained using the inhibition test as the reference standard. Using the Western blot as the reference standard, the HerpesSelect had the highest sensitivity for HSV-2 antibody detection (100%) yet lowest specificity (40%). Results: HSV-2 seroprevalence differed significantly by HSV-2 detection method, ranging from 24.8% with the Western blot to 69.8% with the HerpeSelect ELISA.

HSV-2 IgG serum antibodies were detected using four different methods: HerpeSelect HSV-2 ELISA (nвЂЉ=вЂЉ120), Kalon HSV-2 ELISA (nвЂЉ=вЂЉ120), University of Washington Western blot (nвЂЉ=вЂЉ101) and a recombinant inhibition test (nвЂЉ=вЂЉ93).

Methods: A total of 120 men who were HIV seronegative (aged 18вЂ“24 years) provided blood samples. To date, no study has been conducted to validate HerpeSelect and Kalon type-specific HSV-2 ELISAs using both the Western blot and recombinant gG ELISA inhibition testing as reference standards. Background: In certain parts of Africa, type-specific herpes simplex virus type 2 (HSV-2) ELISAs may have limited specificity.

Western blot herpes test